SCM
ATXS

Soleus Capital Management’s Astria Therapeutics ATXS Stock Holding History

Soleus Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-112,499
Closed -$994K – 70
2021
Q3 		$994K Sell
112,499
-16,668
-13% -$160K 0.15% 64
2021
Q2 		$1.64M Hold
129,167
– – 0.25% 55
2021
Q1 		$2.24M Buy
+129,167
New +$2.33M 0.4% 48

Other funds holding ATXS

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's ATXS Position: Q4 2021 in Review

Soleus Capital Management sold out of Astria Therapeutics (ATXS) in Q4 2021, closing a stake of 112,499 shares — an estimated $994K sold.

Soleus Capital Management first reported a position in ATXS in Q1 2021 and held it in 3 quarters. The position peaked at $2.24M in Q1 2021. 33 funds tracked by Wall St. Rank hold ATXS as of Q4 2021.

  • Soleus Capital Management reported no remaining Astria Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Soleus Capital Management sold 112,499 Astria Therapeutics shares in Q4 2021, an estimated $994K.
  • Soleus Capital Management first reported a position in Astria Therapeutics in Q1 2021 and held it in 3 quarters.
  • Soleus Capital Management's Astria Therapeutics position peaked at $2.24M in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2021.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.